文献速递中枢神经肿瘤放疗

贝伐珠单抗降低复发高级别胶质瘤再程放疗毒性

Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma.
PubMed 文献 · Radiother Oncol · 2019-06-25

PURPOSE: The role of bevacizumab (BEV) in the setting of reirradiation (reRT) of malignant glioma recurrences is poorly defined. At our institution, reRT plus BEV was routinely used until its disapproval for glioma treatment by the European Medical Agency.…

要点

  • 再程放疗联合BEV不改善复发后生存,但显著降低RN/SE发生。
  • 联合BEV组RN/SE绝对发生率21.8%,单纯再放疗组37.8%。
  • 多因素分析中未用BEV是RN/SE唯一危险因素(p=0.026)。

核心结论

  • 同步BEV有效降低再程放疗的治疗毒性,未来再程放疗方案应重新考虑联合BEV。

研究设计与样本

  • BEV组在再程放疗第1天和第15天同步给予BEV 10 mg/kg体重;单纯再放疗组自2017年起未加BEV。
  • 采用Kaplan-Meier法估计复发后生存(PRS)及无RN/SE生存,比例风险模型分析预后因素。

主要发现

  • BEV联合再程放疗124例,单纯再程放疗37例,两组患者、肿瘤及放疗/再放疗相关变量可比。
  • 复发后生存与所采用的再程放疗方案无关。
  • RN/SE绝对发生率:联合BEV组27/124(21.8%),单纯再放疗组14/37(37.8%),p=0.025。
  • 1年RN/SE率:联合BEV组23.9%,单纯再放疗组54.1%,p=0.013。
  • 未调整和调整后的RN/SE风险比在单纯再放疗时均翻倍;多因素模型中未用BEV是RN/SE唯一危险因素(p=0.026)。

关键数值与推荐

  • 放射毒性定义为再程放疗后需类固醇治疗超过6周的经证实症状性放射性坏死(RN)和症状性水肿(SE)。
  • BEV给药方案为再程放疗第1天和第15天同步给予10 mg/kg体重。

临床怎么用

  • 对复发高级别胶质瘤行再程放疗时,可考虑同步联合BEV以降低RN/SE风险,但需注意该结论来自回顾性单中心数据。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The role of bevacizumab (BEV) in the setting of reirradiation (reRT) of malignant glioma recurrences is poorly defined. At our institution, reRT plus BEV was routinely used until its disapproval for glioma treatment by the European Medical Agency. Accordingly, reRT was applied without the addition of BEV since 2017. Here we present for the first time outcome and toxicity profiles of reRT plus BEV and reRT alone for malignant glioma recurrences. PATIENTS AND METHODS: All adult patients consecutively undergoing reRT of a recurrent malignant glioma (37 anaplastic astrocytoma, WHO III; 124 glioblastoma, WHO IV) between 2007 and 2017 were included. In one group of patients, BEV (10 mg/kg bodyweight) was applied concomitantly on days 1 and 15 of reRT. Radiation toxicity referred to clinically significant toxicities of proven symptomatic radionecrosis (RN) and symptomatic oedema (SE) requiring steroid treatment for more than six weeks after reRT. Post-recurrence survival (PRS) and freedom from RN/SE were estimated with the Kaplan-Meier method. Prognostic factors were obtained from proportional hazards models. RESULTS: BEV plus reRT was applied in 124 and reRT alone in 37 patients. Both groups were comparable in terms of their patient-, tumour-, and RT/reRT-related variables. PRS was independent from the applied reRT protocols. RN/SE was less frequently seen after reRT plus BEV absolutely (27/124 (21.8%) vs. 14/37 (37.8%) patients; p = 0.025) and over time (1-year RN/SE rate: 23.9% vs. 54.1%; p = 0.013). The unadjusted and adjusted hazard ratio for RN/SE was doubled in case of reRT alone. Absence of BEV remained the only risk factor for RN/SE in multivariate models (p = 0.026). CONCLUSION: Concomitant BEV effectively reduces treatment toxicity of reRT and should be reconsidered in future reRT protocols.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Fleischmann DF, Jenn J, Corradini S, et al. Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma. Radiother Oncol. 2019. PMID: 31252301. doi:10.1016/j.radonc.2019.06.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。